Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

Leukemia Research
Masamitsu YanadaE H Estey

Abstract

Prognostic relevance of blood counts at complete remission (CR) in acute myeloid leukemia (AML) is not clear. To address this issue, we analyzed 891 AML patients in first CR. From the data of randomly selected 446 patients (training set), we first established optimal cutoffs for neutrophil and platelet counts and hemoglobin level at CR in terms of relapse-free survival (RFS). Patients whose counts were higher than each optimal cutoff were shown to have significantly better RFS (p<0.01 for neutrophil and platelets, and p=0.02 for hemoglobin). Then we tested whether these cutoffs were, after accounting for better known prognostic covariates, also predictive of RFS in the remaining 445 patients (validation set). Our data revealed that higher neutrophil count was independently predictive of longer RFS in the validation set (hazard ratio 1.38, p=0.02), as was higher platelet count (hazard ratio 1.35, p=0.04). These findings suggest that blood counts at CR, information readily available, are useful in prognostication in AML.

References

Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen KrauterGerhard Heil
May 5, 2005·Blood·Martin S TallmanJacob M Rowe
Jul 18, 2006·Heart·F BreuckmannR Erbel
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Oct 19, 2010·Haematologica·Gautam BorthakurJorge E Cortes

❮ Previous
Next ❯

Citations

Jul 19, 2012·Current Oncology Reports·Raya Mawad, Elihu H Estey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.